Snake_Eyes

[Snake_Eyes @GotSnakeEyes]

@NexOptic Get you stuff together. Enough wasting of investors money.

[Snake_Eyes @GotSnakeEyes]

@HIVEDigitalTech You need to have a share price of a minimum $25 to compensate long term shareholders for your 5:1 split. Get it together.

[Snake_Eyes @GotSnakeEyes]

@HIVEDigitalTech @HIVEDigitalTech I bet you won't even respond to our comments.

[Snake_Eyes @GotSnakeEyes]

@HIVEDigitalTech Volatility?!! Hive has just not moved. @HIVEDigitalTech you need to start giving back to investors and show some serious gains. This stock should be up to at least $25 a share to compensate for the reverse split of 1:5. When are investors going to get a return on investment?

[Snake_Eyes @GotSnakeEyes]

@HIVEDigitalTech The biggest problem is the fact that you have diluted shares to remain on the Nasdaq, and have not brought a return on investment thus far. What are your plans to achieve a minimum of a 5x return from the current share price to compensate for the 1:5 reverse split?

[Snake_Eyes @GotSnakeEyes]

https://t.co/WCYTV4KR8d

[(Inspector)AMCBiggums @AMCbiggums]

so ken just admits they control stock priceS?

[Snake_Eyes @GotSnakeEyes]

@NexOptic So when are investors going see any sales reports of your product(s)?

[Sernova @Sernovabio]

Today, we announced new positive interim data from our ongoing Phase 1/2 clinical trial evaluating our novel #CellTherapy platform in people living with #Type1Diabetes (#T1D). Read our press release to learn more: https://t.co/TJOj4VwK1N $SEOVF $SVA #Diabetes

[Sernova @Sernovabio]

Today at the 2023 @AmThyroidAssn Annual Meeting, we presented new preclinical data evaluating our novel cell therapy platform as a potential treatment for post-operative #hypothyroidism. Learn more about the data here: https://t.co/OBiILgxhKg $SVA $SEOVF

[Snake_Eyes @GotSnakeEyes]

@ctvottawa Good for you guys. I have no quams with how someone chooses to lead their life, but let's start to act like adults around the world instead of every person out there looking to be put in the spotlight.

[Snake_Eyes @GotSnakeEyes]

@SernovaCorp I like Dr. Toleikis, but his strength is science, not public speaking or publicity. We need to have someone with better people skills who can get the crowd excited. Everyone has strengths and weaknesses. No fault. Just need to assign the right people for the right job.

[Sernova @Sernovabio]

At Sernova, we are advancing our Cell Pouch System™ with the goal of improving the quality of life for patients with chronic diseases including #Type1Diabetes, #Hypothyroidism, and #HemophiliaA. Learn more about our #CellTherapy approach on our website: https://t.co/yuSrgNEEhC

[Sernova @Sernovabio]

Our partners at @Evotec have developed a differentiated GMP manufacturing process that allows for the commercial-scale production of induced pluripotent stem cell-derived islet-like clusters for use in our Cell Pouch System™. Check out the graphic below for more details!

[Snake_Eyes @GotSnakeEyes]

@ShrubJon @HiveBlockchain I agree... this is such a waste of investors money. Smarten up.

[Snake_Eyes @GotSnakeEyes]

@HiveBlockchain Who cares. Is this what you're being paid to do?! What a waste of time and resources. Shape up.

[Snake_Eyes @GotSnakeEyes]

@HiveBlockchain Listen... I appreciate the enthusiasm, but let's start taking that effort and putting it into generating return for investors.

[Snake_Eyes @GotSnakeEyes]

@ibrahimdirim @SernovaCorp @protolifemedia First cohert in Phase 1 has been insulin independent for almost 3 years now. That's what they're talking about. This is a functional cure for sure. What they have now works with donor islets. Thing is, there are only so many donors. They are working with Evotech on stemcells.

[Snake_Eyes @GotSnakeEyes]

@ibrahimdirim @SernovaCorp @protolifemedia It means insurance will pay for it. Not only is it cheaper for insurance, it takes a load off the whole medical and pharmaceutical industry. This will alot resources to focus on other illnesses.

[Sernova @Sernovabio]

Recently, our CEO, Dr. Philip Toleikis, spoke with @protolifemedia on the advancements of our Cell Pouch System™ to develop a potential ‘functional cure’ for #T1D patients. #diabetes. Read here: https://t.co/9R5q4xjzXT